Medtronic, having received FDA approval last year, is now introducing its MiniMed 670G hybrid closed loop insulin delivery system to the U.S. market. The first such system to become available, the MiniMed 670G utilizes Medtronic’s SmartGuard HCL algorithm to deduce when and how much insulin to deliver, yet allowing the patients themselves to make changes when necessary.
The Guardian Sensor 3 within the package that measures glucose levels every five minutes can be worn continuously for up to a week, including during showering and other activities. It has a self-check feature that automatically helps keep the sensor accurate from measurement to measurement, helping to guarantee quality readings and therefore correct insulin delivery.
Data from the pivotal trial of the MiniMed 670G system published in the Journal of the American Medical Association (JAMA) demonstrated less glycemic variability, more time in the target range, less exposure to hypoglycemia and hyperglycemia, and reduced A1c for patients on the system.1 Importantly, real-world use of the system in the Customer Training Phase has shown consistent improved outcomes across several important areas including Time in Range (74 percent) and greater median time in Auto Mode (92 percent).2 Real-world use of the Guardian Sensor 3 also demonstrates continued strong performance and reliability of the company’s most accurate sensor to date with a MARD of 10.56 percent against BG3 – confirming why it’s the only continuous glucose monitor trusted and approved by the FDA to power a hybrid closed loop system.
Here’s a Medtronic promo video for the MiniMed 670G:
Product page: MiniMed 670G…